MedTrace Logo

Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors

NCT02857920 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2020-09-14

No results posted yet for this study

Summary

The aim of this study is the safety and efficacy of Bevacizumab plus allogeneic natural killer (NK) immunotherapy to many kinds of recurrent solid tumors.

Conditions

  • Malignant Solid Tumour

Interventions

DRUG

Bevacizumab

7.5 mg/kg, i.v, once every 3 weeks (continuous)

BIOLOGICAL

NK immunotherapy

Each treatment: 8\~10 billion cells in all, transfusion in 3 times, i.v.

Sponsors & Collaborators

  • Shenzhen Hank Bioengineering Institute

    collaborator OTHER

  • Fuda Cancer Hospital, Guangzhou

    lead OTHER

Principal Investigators

  • Jibing Chen, MD, PhD · Fuda Cancer Hospital, Guangzhou

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-01
Primary Completion
2017-08-01
Completion
2019-08-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02857920 on ClinicalTrials.gov